Nuformix PLC Adviser Appointments (2273A)
February 01 2022 - 12:59AM
UK Regulatory
TIDMNFX
RNS Number : 2273A
Nuformix PLC
01 February 2022
1 February 2022
Nuformix plc
("Nuformix" or the "Company")
Adviser Appointments
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce the appointment of Stanford
Capital Partners Limited as Financial Adviser and Broker to the
Company, with immediate effect.
Additionally, IFC Advisory Limited have been appointed as the
Company's new financial public relations and investor relations
adviser with immediate effect.
Enquiries:
Nuformix plc
Dr Alastair Riddell, Executive Chairman Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe
Zach Cohen +44 (0) 20 3934 6630
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase I-ready assets with potential for significant value and
early licensing opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPBKDBBCBKDQDN
(END) Dow Jones Newswires
February 01, 2022 01:59 ET (06:59 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024